Normunity, a Boston, MA- and New Haven, CT-based biotechnology company developing new anti-cancer therapies, raised $75M in Series B funding.
The round was led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. The Board of Directors will be expanded to include David Parry, PhD (Samsara), Sara Nayeem, MD (Enavate) and Marie-Clare Peakman, MD (Pfizer Ventures).
The company intends to use the funds to advance its lead program, NRM-823, a first-in-class T cell engager that binds a novel, highly specific tumor target expressed on multiple types of solid tumors.
Led by CEO Rachel Humphrey, Normunity is a biotechnology company creating new anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Its lead program, NRM‑823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025.
FinSMEs
13/01/2025